Active Ingredient History
Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc., the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Psoriasis (approved 2003)
Anemia, Aplastic (Phase 1)
Arthritis, Psoriatic (Phase 2)
Dermatitis, Atopic (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Graft vs Host Disease (Phase 3)
Kidney Failure, Chronic (Phase 1)
Kidney Transplantation (Phase 2)
Lichen Planus (Phase 2)
Lymphoma (Phase 1)
Pharmacokinetics (Phase 1)
Pityriasis Rubra Pilaris (Phase 4)
Psoriasis (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
